Large-scale population analysis of GLP-1 drug association with major cardiovascular events confirms significant reduction in heart attack, stroke, and cardiovascular death.
Key findingLarge-scale population analysis of GLP-1 drug association with major cardiovascular events confirms
What the researchers found
Large-scale population analysis of GLP-1 drug association with major cardiovascular events confirms significant reduction in heart attack, stroke, and cardiovascular death.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Comprehensive search through March 2025 across four databases. No significant association with diabetic retinopathy development or progression.
How the study worked
In publication.
Who was studied
Diabetic patients using GLP-1 drugs across clinical trials and observational studies
What this study cannot tell us
In publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide therapeutic knowledge.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) - a systematic review and meta-analysis.
Frontiers in medicine, 12, 1639704
Citation
Alwafi, Hassan; Al-Harbi, Sarah Saleh; Aladwani, Ghada Ahmad; Alsanosi, Safaa M; Oyelade, Tope; Almalki, Fahd; Thalib, Husna Irfan; Naser, Abdallah Y; Alfahmi, Manal Z; AlOtaibi, Basil; Fuad, Samra; Zubair, Mohammed Talha Mohammed; Aldhahir, Abdulelah M; Insani, Widya N; Alqarni, Abdullah A; Alqahtani, Jaber S; Ashoor, Deema S; Dairi, Mohammad Saleh. (2025). Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) - a systematic review and meta-analysis.. Frontiers in medicine, 12, 1639704. https://doi.org/10.3389/fmed.2025.1639704